{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["Q2-2025"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":0,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Q2-2025","index":0,"n_rows":114,"n_cols":5,"rows_kept":114,"cut":false,"hidden":false,"merged":[]}
["Therapeutic area","Project ","Phase ","NCT number ","Title"]
["Immunology","amlitelimab \n(OX40L mAb)","\nPhase 2\n","NCT05492578","Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)"]
["Immunology","amlitelimab \n(OX40L mAb)","\nPhase 2\n","NCT06015308","A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo (HYDRO)"]
["Immunology","amlitelimab \n(OX40L mAb)","\nPhase 2\n","NCT05769777","Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)"]
["Immunology","amlitelimab \n(OX40L mAb)","\nPhase 3\n","NCT06130566","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)"]
["Immunology","amlitelimab \n(OX40L mAb)","Phase 3","NCT06181435","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)"]
["Immunology","amlitelimab \n(OX40L mAb)","Phase 3","NCT06224348","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)"]
["Immunology","amlitelimab \n(OX40L mAb)","Phase 3","NCT06241118","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)"]
["Immunology","amlitelimab \n(OX40L mAb)","Phase 3","NCT06407934","A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)"]
["Immunology","amlitelimab \n(OX40L mAb)","\nPhase 2\n","NCT05421598","Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma (TIDE-asthma)"]
["Immunology","amlitelimab \n(OX40L mAb)","\nPhase 2\n","NCT06033833","Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study (RIVER-ASTHMA)"]
["Immunology","amlitelimab \n(OX40L mAb)","Phase 2","NCT06195072","Platform Clinical Study for Conquering Scleroderma (CONQUEST)"]
["Immunology","amlitelimab \n(OX40L mAb)","Phase 2","NCT06444451","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata"]
["Immunology","amlitelimab \n(OX40L mAb)","Phase 2","NCT06557772","A Phase 2a/​b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease"]
["Immunology","frexalimab \n(CD40L mAb)","\nPhase 2\n","NCT05039840","Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus (APATURA)"]
["Immunology","frexalimab \n(CD40L mAb)","\nPhase 2\n","NCT06111586","FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)"]
["Immunology","balinatunfib\n(Oral TNFR1 signaling inhibitor)","\nPhase 2\n","NCT06073093","A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis (SPECIFI-RA)"]
["Immunology","balinatunfib\n(Oral TNFR1 signaling inhibitor)","\nPhase 2\n","NCT06637631","A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. (SPECIFI-CD)"]
["Immunology","balinatunfib\n(Oral TNFR1 signaling inhibitor)","\nPhase 2\n","NCT06867094","A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis (SPECIFI-UC)"]
["Immunology","itepekimab \n(IL33 mAb)","\nPhase 3\n","NCT04701983","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/​REGN3500/​Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)"]
["Immunology","itepekimab \n(IL33 mAb)","\nPhase 3\n","NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)"]
["Immunology","itepekimab \n(IL33 mAb)","\nPhase 2\n","NCT05326412","Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (AERIFY-3)"]
["Immunology","itepekimab \n(IL33 mAb)","Phase 3","NCT06834347","A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (CEREN1)"]
["Immunology","itepekimab \n(IL33 mAb)","Phase 3","NCT06834360","A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (CEREN2)"]
["Immunology","itepekimab \n(IL33 mAb)","\nPhase 2\n","NCT06280391","A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis"]
["Immunology","itepekimab \n(IL33 mAb)","\nPhase 2\n","NCT06691113","A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps"]
["Immunology","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT04520451","Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients"]
["Immunology","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT05107115","Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)"]
["Immunology","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT05104892","Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma"]
["Immunology","lunsekimig \n(IL13 x TSLP Nanobody VHH)","\nPhase 2\n","NCT06102005","Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (AIRCULES)"]
["Immunology","lunsekimig \n(IL13 x TSLP Nanobody VHH)","\nPhase 2\n","NCT06609239","Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma. (AIRPHRODITE)"]
["Immunology","lunsekimig \n(IL13 x TSLP Nanobody VHH)","\nPhase 2\n","NCT06676319","Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)"]
["Immunology","lunsekimig \n(IL13 x TSLP Nanobody VHH)","\nPhase 2\n","NCT06454240","A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps"]
["Immunology","lunsekimig \n(IL13 x TSLP Nanobody VHH)","Phase 2","NCT06790121","A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis"]
["Immunology","duvakitug\n(TL1A mAb)","\nPhase 2\n","NCT05499130","A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)"]
["Immunology","duvakitug\n(TL1A mAb)","\nPhase 2\n","NCT05668013","A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease"]
["Immunology","SAR444656 \n(IRAK4 degrader)","\nPhase 2\n","NCT06058156","Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (ADVANTA)"]
["Immunology","SAR444656 \n(IRAK4 degrader)","\nPhase 2\n","NCT06028230","A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (ZEN)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid (LIBERTY-BP)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\nPhase 3\n","NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\nPhase 3\n","NCT05526521","A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants\n#2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT05831176","A  Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis (ENGAGE)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\nPhase 3\n","NCT05263206","Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO- CHIC)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\nPhase 3\n","NCT06687967","A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\nPhase 3\n","NCT06687980","A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)"]
["Immunology","Dupixent \n(IL4xIL13 mAb) ","\nPhase 2\n","NCT05731128","A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged #18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))"]
["Immunology","teplizumab\n(CD3 mAb )","\nPhase 4\n","NCT05757713","Teplizumab in Pediatric Stage 2 Type 1 Diabetes (PETITE-T1D)"]
["Immunology","teplizumab\n(CD3 mAb )","Observational","NCT04598893","Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)"]
["Immunology","Rezurock \n(ROCK2 inhibitor)","\nPhase 3\n","NCT06082037","A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (ROCKaspire)"]
["Immunology","eclitasertib \n(RIPK1 inhibitor)","\nPhase 2\n","NCT05588843","Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (RESOLUTE)"]
["Immunology","riliprubart\n(C1S inhibitor)","\nPhase 2\n","NCT05156710","BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)"]
["Immunology","brivekimig \n(TNFaxOX40L Nanobody VHH)","\nPhase 2\n","NCT05849922","A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa (HS OBTAIN)"]
["Immunology","brivekimig \n(TNFaxOX40L Nanobody VHH)","Phase 2","NCT06812988","Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule (T1D OBTAIN)"]
["Immunology","SAR444336 \n(Non-beta IL2 Synthorin)","\nPhase 1\n","NCT05876767","Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants"]
["Immunology","SAR446959 \n(MMP13 x ADAMTS5 x CAP Nanobody VHH)","\nPhase 1\n","NCT06704932","A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee"]
["Immunology","SAR448501\n(CD20 bispecific mAb)","\nPhase 1\n","NCT06647069","DR-0201 in Subjects With Autoimmune Diseases"]
["Neurology","frexalimab \n(CD40L mAb)","\nPhase 3\n","NCT06141473","Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (FREXALT)"]
["Neurology","frexalimab \n(CD40L mAb)","\nPhase 2\n","NCT04879628","Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis"]
["Neurology","frexalimab \n(CD40L mAb)","\nPhase 3\n","NCT06141486","Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)"]
["Neurology","tolebrutinub \n(BTK inhibitor)","\nPhase 3\n","NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)"]
["Neurology","tolebrutinub \n(BTK inhibitor)","\nPhase 3\n","NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)"]
["Neurology","tolebrutinub \n(BTK inhibitor)","\nPhase 3\n","NCT06372145","A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis"]
["Neurology","riliprubart\n(C1S inhibitor)","\nPhase 2\n","NCT04658472","Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"]
["Neurology","riliprubart\n(C1S inhibitor)","Phase 3","NCT06290128","A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work (MOBILIZE)"]
["Neurology","riliprubart\n(C1S inhibitor)","Phase 3","NCT06290141","A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (VITALIZE)"]
["Neurology","riliprubart\n(C1S inhibitor)","Phase 3","NCT06859099","Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP (LTS)"]
["Neurology","SAR446159 \n(SynucleinxIGF1R mAb)","\nPhase 1\n","NCT05756920","This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants"]
["Neurology","SAR402663\n(Gene therapy)","\n• Phase 1\n• Phase 2\n","NCT06660667","A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration"]
["Rare diseases","rilzabrutinib \n(BTK inhibitor)","\nPhase 3\n","NCT04562766","Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)"]
["Rare diseases","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT03395210","A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)"]
["Rare diseases","rilzabrutinib \n(BTK inhibitor)","\nPhase 2\n","NCT05002777","Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)"]
["Rare diseases","Qfitlia\n(RNAi targeting anti-thrombin)  ","\n• Phase 2\n• Phase 3\n","NCT03974113","Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)"]
["Rare diseases","Qfitlia\n(RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03754790","Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX (ATLAS-OLE)"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 3\n","NCT05280548","A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease (CARAT)"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 3\n","NCT05206773","A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease (PERIDOT)"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 3\n","NCT05222906","Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (LEAP2MONO)"]
["Rare diseases","venglustat \n(oral GCS inhibitor) ","\nPhase 2\n","NCT02843035","Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension (LEAP)"]
["Rare diseases","Nexviazyme \n(Enzyme replacement therapy) ","\nPhase 2\n","NCT03019406","A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (Mini-COMET)"]
["Rare diseases","SAR447537\n(AAT fusion protein)","Phase 2","NCT05856331","Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema (ELEVAATE)"]
["Rare diseases","SAR447537\n(AAT fusion protein)","Phase 2","NCT05897424","Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema (ELEVAATE OLE)"]
["Rare diseases","rilzabrutinib \nfrexalimab\nbrivekimig","Phase 2","NCT06500702","A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)"]
["Oncology","Sarclisa \n(CD38 mAb)","\nPhase 3\n","NCT04270409","A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma"]
["Oncology","Sarclisa \n(CD38 mAb)","\nPhase 3\n","NCT03617731","Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)"]
["Oncology","Sarclisa \n(CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol"]
["Oncology","Sarclisa \n(CD38 mAb)","\nPhase 2\n","NCT05704049","A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma"]
["Oncology","Sarclisa \n(CD38 mAb)","\nPhase 3\n","NCT05405166","SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (IRAKLIA)"]
["Oncology","Sarclisa \n(CD38 mAb)","\nPhase 3\n","NCT04483739","Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia)"]
["Oncology","SAR445953 \n(CEACAM5-Topo1 ADC)","\nPhase 1\n","NCT06131840","A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors"]
["Oncology","SAR445877 \n(PD1xIL15 fusion protein)","\n• Phase 1\n• Phase 2\n","NCT05584670","A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors"]
["Oncology","SAR447873 (SSTR targeting alpha-emitter therapy)","Phase 2","NCT05153772","Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (ALPHAMEDIX02)"]
["Oncology","SAR446523\n(GPRC5D mAb)","Phase 1","NCT06630806","A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/​Refractory Myeloma"]
["Vaccines","SP0256 \n(mRNA vaccine)","\n• Phase 1\n• Phase 2\n","NCT06134648","Study of a Respiratory Syncytial Virus/ Human Metapneumovirus Vaccine Candidate"]
["Vaccines","SP0256 \n(mRNA vaccine)","Phase 1","NCT06583031","Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years"]
["Vaccines","SP0256 \n(mRNA vaccine)","\n• Phase 1\n• Phase 2\n","NCT06686654","Study of a Human Metapneumovirus/​Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older"]
["Vaccines","SP0268 \n(mRNA vaccine)","\n• Phase 1\n• Phase 2\n","NCT06316297","Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne"]
["Vaccines","SP0087 \n(Vero cell vaccine)","\nPhase 3\n","NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults"]
["Vaccines","SP0125 \n(Live attenuated vaccine)","Phase 3","NCT06252285","Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)"]
["Vaccines","SP0125 \n(Live attenuated vaccine)","Phase 3","NCT06397768","Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (CORAL)"]
["Vaccines","SP0125 \n(Live attenuated vaccine)","Phase 3","NCT06705140","A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL)"]
["Vaccines","SP0230 \n(5-valent (ABCWY) vaccine)","\n• Phase 1\n• Phase 2\n","NCT06128733","Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents"]
["Vaccines","SP0230 \n(5-valent (ABCWY) vaccine)","\n• Phase 1\n• Phase 2\n","NCT06647407","Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants"]
["Vaccines","SP0237 \n(mRNA vaccine)","\n• Phase 1\n• Phase 2\n","NCT06744205","A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older"]
["Vaccines","Fluzone HD \n(Multivalent inactivated vaccine)","Phase 3","NCT06641180","Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age"]
["Vaccines","SP0202 \n(21-valent conjugate vaccine)","Phase 3","NCT06736041","Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age"]
["Vaccines","SP0202 \n(21-valent conjugate vaccine)","Phase 3","NCT06838000","Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents"]
["Vaccines","SP0202 \n(21-valent conjugate vaccine)","Phase 3","NCT06975878","Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age"]
["Vaccines","SP0287 \n(Fluzone HD + Nuvaxovid combination vaccine)","\n• Phase 1\n• Phase 2\n","NCT06695117","Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older"]
["Vaccines","SP0287 \n(Flublok + Nuvaxovid combination vaccine)","\n• Phase 1\n• Phase 2\n","NCT06695130","Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older"]
["Vaccines","SP0335 \n(Inactivated adjuvanted vaccine)","Phase 2","NCT06560151","BARDA BP-I-23-001 H5 Influenza"]
["Vaccines","SP0289 \n(mRNA vaccine)","\n• Phase 1\n• Phase 2\n","NCT06727058","Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older"]
["Vaccines","SP0289 \n(mRNA vaccine)","\n• Phase 1\n• Phase 2\n","NCT06907511","Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older"]
["Vaccines","SP0291\n(mRNA vaccine)","Phase 1","NCT06604767","Study of a Respiratory Syncytial Virus/​Human Metapneumovirus/​Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older"]
["Vaccines","SP0218 \n(Vero cell vaccine)","Phase 3","NCT07002060","Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults"]
["Vaccines","SP0269\n(mRNA vaccine)","\n• Phase 1\n• Phase 2\n","NCT06891417","Phase 1/​2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years"]